Should I buy or sell Karuna Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares. View KRTX analyst ratings or view top-rated stocks .

What is Karuna Therapeutics' stock price target for 2024?

16 equities research analysts have issued 12 month price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $225.00 to $330.00. On average, they expect the company's stock price to reach $293.92 in the next year. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts .

How have KRTX shares performed in 2024?

Karuna Therapeutics' stock was trading at $316.51 at the beginning of the year. Since then, KRTX stock has increased by 4.2% and is now trading at $329.83. View the best growth stocks for 2024 here .

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KRTX earnings forecast .

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by $0.36. The business's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.22) EPS.

What ETFs hold Karuna Therapeutics' stock?

ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) , iShares Neuroscience and Healthcare ETF (IBRN) , Principal Healthcare Innovators ETF (BTEC) , Invesco Nasdaq Biotechnology ETF (IBBQ) , iShares Biotechnology ETF (IBB) , ProShares Ultra Nasdaq Biotechnology (BIB) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) . Vanguard Small-Cap Value ETF (VBR) .

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Pfizer (PFE) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , AT&T (T) , Target (TGT) and Walt Disney (DIS) .

When did Karuna Therapeutics IPO?

Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KRTX Stock Alerts

$329.83

0.00 (0.00%)

(As of 04/1/2024)

Compare

Today's Range: $329.83
▼
$329.83
50-Day Range: $313.97
▼
$329.83
52-Week Range: $158.38
▼
$329.99

Volume: 5 shs
Average Volume: 832,048 shs
Market Capitalization: $12.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $293.92

Get Karuna Therapeutics alerts:

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 10.9% Downside
$293.92 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$3.17 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($11.96) to ($7.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.05 out of 5 stars

Medical Sector

910th out of 914 stocks

Pharmaceutical Preparations Industry

414th out of 417 stocks

1.2

Analyst's Opinion

Consensus Rating
Karuna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 10 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Karuna Therapeutics has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for KRTX.

0.0

Dividend Strength

Dividend Yield
Karuna Therapeutics does not currently pay a dividend.
Dividend Growth
Karuna Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KRTX.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,172,350.00 in company stock.
Percentage Held by Insiders
13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.96) to ($7.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Karuna Therapeutics has a P/B Ratio of 9.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRTX Stock News Headlines

April 9, 2024 | msn.com

Seaport Therapeutics has $100 million to develop new ways to treat mental disorders

March 15, 2024 | finance.yahoo.com

Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 15, 2024 | ca.finance.yahoo.com

KRTX May 2024 210.000 call

March 14, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)

March 4, 2024 | finance.yahoo.com

Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position

February 26, 2024 | msn.com

Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb

February 23, 2024 | benzinga.com

1KRTX : Karuna Therapeutics: Q4 Earnings Insights

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 22, 2024 | msn.com

Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29

February 22, 2024 | finance.yahoo.com

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

February 22, 2024 | businesswire.com

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

February 21, 2024 | seekingalpha.com

Bronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of Process

February 18, 2024 | seekingalpha.com

Karuna Therapeutics: Getting Sold Short

February 17, 2024 | finance.yahoo.com

KRTX Mar 2024 320.000 call

February 17, 2024 | finance.yahoo.com

KRTX Mar 2024 260.000 put

February 17, 2024 | finance.yahoo.com

KRTX Mar 2024 330.000 call

February 17, 2024 | finance.yahoo.com

KRTX Mar 2024 280.000 put

February 14, 2024 | businesswire.com

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

January 31, 2024 | finance.yahoo.com

Karuna Therapeutics (KRTX) Rose on Acquisition Announcement

January 29, 2024 | msn.com

Karuna’s KarXT tops Evaluate’s most anticipated drug list

January 22, 2024 | msn.com

Bristol-Myers almost lost Karuna buyout to third party

January 19, 2024 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Karuna Therapeutics, Inc. (KRTX)

January 12, 2024 | finance.yahoo.com

Chief Medical Officer Stephen Brannan Sells 15,000 Shares of Karuna Therapeutics Inc

December 31, 2023 | businesswire.com

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna ...

December 29, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)

December 29, 2023 | msn.com

JP Morgan Downgrades Karuna Therapeutics (KRTX)

See More Headlines

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KRTX
CUSIP: N/A
CIK: 1771917
Web: karunatx.com
Phone: (857) 449-2244
Fax: N/A
Employees: 339
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $293.92
High Stock Price Target: $330.00
Low Stock Price Target: $225.00
Potential Upside/Downside: -10.9%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-433,680,000.00
Net Margins: N/A
Pretax Margin: -66,209.48%
Return on Equity: -31.63%
Return on Assets: -30.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.31
Quick Ratio: 19.31

Sales & Book Value

Annual Sales: $654,000.00
Price / Sales: 19,239.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $33.24 per share
Price / Book: 9.92

Miscellaneous

Outstanding Shares: 38,148,000
Free Float: 33,157,000
Market Cap: $12.58 billion
Optionable: Optionable
Beta: 1.18

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Andrew Craig Miller Ph.D. (Age 42)
Founder and President of Research & Development
Comp: $835.4k
Dr. Stephen K. Brannan (Age 68)
Chief Medical Officer
Comp: $751.75k
Mr. William Meury (Age 56)
President, CEO & Director
Mr. Jason Parker Brown
Chief Financial Officer
Ms. Alexis Smith
Vice President of Corporate Affairs & Investor Relations
Ms. Mia Kelley J.D.
General Counsel
Mr. Frank Truslow
Senior Vice President of Corporate Development
Mr. Jonathan Rosin
Chief Human Resources Officer
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor
Dr. Ronald N. Marcus M.D. (Age 66)
Senior Vice President of Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares.
View KRTX analyst ratings or view top-rated stocks.
What is Karuna Therapeutics' stock price target for 2024?: 16 equities research analysts have issued 12 month price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $225.00 to $330.00. On average, they expect the company's stock price to reach $293.92 in the next year. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.
How have KRTX shares performed in 2024?: Karuna Therapeutics' stock was trading at $316.51 at the beginning of the year. Since then, KRTX stock has increased by 4.2% and is now trading at $329.83.
View the best growth stocks for 2024 here.
When is Karuna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KRTX earnings forecast.
How were Karuna Therapeutics' earnings last quarter?: Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by $0.36. The business's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.22) EPS.

What ETFs hold Karuna Therapeutics' stock?: ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).Vanguard Small-Cap Value ETF (VBR).
What other stocks do shareholders of Karuna Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).
When did Karuna Therapeutics IPO?: Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Karuna Therapeutics?: Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

Karuna Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Karuna Therapeutics Stock (NASDAQ:KRTX)

KRTX Stock Price History

KRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KRTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™